This is a preview of subscription content, log in via an institution to check access.
Reference
Stander M, et al. Cost-Effectiveness of Lapatinib in Metastatic Breast Cancer: a Middle Income Perspective. 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN87, 18 May 2013.
Rights and permissions
About this article
Cite this article
Lapatinib dominates in advanced breast cancer. PharmacoEcon Outcomes News 680, 6 (2013). https://doi.org/10.1007/s40274-013-0467-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0467-6